Maccura Biotechnology Co.Ltd (300463.SZ)
- Previous Close
12.13 - Open
11.71 - Bid 12.58 x --
- Ask 12.59 x --
- Day's Range
12.20 - 12.75 - 52 Week Range
9.90 - 17.40 - Volume
8,292,144 - Avg. Volume
5,760,964 - Market Cap (intraday)
7.699B - Beta (5Y Monthly) --
- PE Ratio (TTM)
20.61 - EPS (TTM)
0.61 - Earnings Date --
- Forward Dividend & Yield 0.35 (2.88%)
- Ex-Dividend Date May 29, 2023
- 1y Target Est
--
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It provides SARS-COV-2(COVID-19) products that includes nucleic acid detection kit and other products; glucometers; POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR kit; and pathology products. Maccura Biotechnology Co.Ltd was incorporated in 1994 and is based in Chengdu, China.
www.maccura.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: 300463.SZ
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300463.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300463.SZ
Valuation Measures
Market Cap
7.43B
Enterprise Value
7.06B
Trailing P/E
19.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.47
Price/Book (mrq)
1.17
Enterprise Value/Revenue
2.35
Enterprise Value/EBITDA
15.84
Financial Highlights
Profitability and Income Statement
Profit Margin
11.15%
Return on Assets (ttm)
3.36%
Return on Equity (ttm)
4.66%
Revenue (ttm)
2.84B
Net Income Avi to Common (ttm)
316.19M
Diluted EPS (ttm)
0.61
Balance Sheet and Cash Flow
Total Cash (mrq)
959.7M
Total Debt/Equity (mrq)
10.60%
Levered Free Cash Flow (ttm)
-288.99M
Research Analysis: 300463.SZ
Company Insights: 300463.SZ
300463.SZ does not have Company Insights